HardEndocrinologyObesity and cardiovascular risk pharmacotherapyau-amcau-racgpau-racp
A 58-year-old man with BMI 34 kg/m² and established coronary artery disease has well-controlled type 2 diabetes on metformin. He asks about pharmacological options for weight loss that may also reduce his cardiovascular risk. Which class of medication has recent evidence in Australia for reducing major adverse cardiovascular events in overweight or obese adults with cardiovascular disease but without diabetes?